Prediction of drug combination effects with a minimal set of experiments

High-throughput drug combination screening provides a systematic strategy to discover unexpected combinatorial synergies in pre-clinical cell models. However, phenotypic combinatorial screening with multi-dose matrix assays is experimentally expensive, especially when the aim is to identify selective combination synergies across a large panel of cell lines or patient samples. Here, we implement DECREASE, an efficient machine learning model that requires only a limited set of pairwise dose–response measurements for accurate prediction of drug combination synergy in a given sample. Using a compendium of 23,595 drug combination matrices tested in various cancer cell lines and malaria and Ebola infection models, we demonstrate how cost-effective experimental designs with DECREASE capture almost the same degree of information for synergy and antagonism detection as the fully measured dose–response matrices. Measuring only the matrix diagonal provides an accurate and practical option for combinatorial screening. The minimal-input web implementation enables applications of DECREASE to both pre-clinical and translational studies.Drug combinations are often an effective means of managing complex diseases, but understanding the synergies of drug combinations requires extensive resources. The authors developed an efficient machine learning model that requires only a limited set of pairwise dose–response measurements for the accurate prediction of synergistic and antagonistic drug combinations.

[1]  W. Janzen,et al.  Screening technologies for small molecule discovery: the state of the art. , 2014, Chemistry & biology.

[2]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[3]  Peter J. Park,et al.  Systematic Identification of Synergistic Drug Pairs Targeting HIV , 2012, Nature Biotechnology.

[4]  Sam Michael,et al.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.

[5]  Diana Yu,et al.  Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma , 2015, Scientific Reports.

[6]  S. Chakradhar All in one: Researchers create combination drugs for diabetes and obesity , 2016, Nature Medicine.

[7]  A. Vatrella,et al.  The potential of biologics for the treatment of asthma , 2012, Nature Reviews Drug Discovery.

[8]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[9]  Sam Michael,et al.  High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations , 2015, Scientific Reports.

[10]  A. Biankin,et al.  Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer , 2017, Gut.

[11]  J. H. Venter On Estimation of the Mode , 1967 .

[12]  Bernd Bischl,et al.  mlrMBO: A Modular Framework for Model-Based Optimization of Expensive Black-Box Functions , 2017, 1703.03373.

[13]  Tianqi Chen,et al.  XGBoost: A Scalable Tree Boosting System , 2016, KDD.

[14]  Joel Greshock,et al.  High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. , 2016, Cancer research.

[15]  A. C. Eziefula Artesunate-mefloquine: a malaria treatment for African children? , 2016, The Lancet. Infectious diseases.

[16]  W. Bolosky,et al.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies , 2017, Proceedings of the National Academy of Sciences.

[17]  Krister Wennerberg,et al.  Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells , 2016, Molecular Cancer.

[18]  Krister Wennerberg,et al.  Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513] , 2017, Computational and structural biotechnology journal.

[19]  Yair Benita,et al.  An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies , 2016, Molecular Cancer Therapeutics.

[20]  Jing Tang,et al.  What is synergy? The Saariselkä agreement revisited , 2015, Front. Pharmacol..

[21]  Asher Mullard Microfluidics platform lowers barrier to drug combination screening , 2018, Nature Reviews Drug Discovery.

[22]  Dennis Wang,et al.  Combenefit: an interactive platform for the analysis and visualization of drug combinations , 2016, Bioinform..

[23]  Uri Alon,et al.  Prediction of multidimensional drug dose responses based on measurements of drug pairs , 2016, Proceedings of the National Academy of Sciences.

[24]  Sanna Timonen,et al.  Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. , 2018, Cancer research.

[25]  Christian Melander,et al.  Combination approaches to combat multidrug-resistant bacteria. , 2013, Trends in biotechnology.

[26]  T. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[27]  James J Collins,et al.  Chemogenomics and orthology‐based design of antibiotic combination therapies , 2016, Molecular systems biology.

[28]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[29]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[30]  Sudhindra R Gadagkar,et al.  Computational tools for fitting the Hill equation to dose-response curves. , 2015, Journal of pharmacological and toxicological methods.

[31]  C. I. Bliss THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[32]  Andreas Bender,et al.  Prediction of synergistic drug combinations , 2017 .

[33]  Florent Baty,et al.  Dose-Response Analysis Using R , 2015, PLoS ONE.

[34]  Paul Shinn,et al.  Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. , 2018, The Journal of infectious diseases.

[35]  Noel Southall,et al.  Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria , 2016, Emerging microbes & infections.

[36]  Krister Wennerberg,et al.  Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. , 2015, Chemistry & biology.

[37]  Yu-Jin Zhang,et al.  Nonnegative Matrix Factorization: A Comprehensive Review , 2013, IEEE Transactions on Knowledge and Data Engineering.

[38]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Rachel M. Webster Combination therapies in oncology , 2016, Nature Reviews Drug Discovery.

[40]  Sitta Sittampalam,et al.  Open access high throughput drug discovery in the public domain: a Mount Everest in the making. , 2010, Current pharmaceutical biotechnology.

[41]  U. Jaeger,et al.  Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. , 2010, Blood.

[42]  S. Loewe The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[43]  Søren Brunak,et al.  Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities , 2016, Molecular Cancer Therapeutics.

[44]  T. Bollenbach,et al.  Systematic discovery of drug interaction mechanisms , 2015, Molecular systems biology.

[45]  Tero Aittokallio,et al.  SynergyFinder: a web application for analyzing drug combination dose–response matrix data , 2017, Bioinform..

[46]  Larry Rubinstein,et al.  The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. , 2017, Cancer research.

[47]  Berenbaum Mc What is synergy? , 1989, Pharmacological reviews.